OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Xiaomi Shares Jump on Europe EV Expansion Plan 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Milei Threatens Falkland Oil Firms With Sanctions 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
France Targets Shein, Temu With Fast-Fashion Fees 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
OpenAI Rejects Apple Trade Secret Theft Claims 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Add as a preferred source on Google
UTRECHT, The Netherlands, March 06, 2018 -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that Ton Logtenberg, Ph.D., Chief Executive Officer, will present a company overview at the Cowen & Co. 38th Annual Health Care Conference on Tuesday, March 13, 2018, at 10:00 a.m. ET.
A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl. An archived presentation will be available for 90 days.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. Merus’ most advanced bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 2 combination trial in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in gastric, ovarian, endometrial and non-small cell lung cancers. Merus’ second most advanced bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as MCLA-145, which is designed to bind to PD-L1 and a non-disclosed second immunomodulatory target, which is being developed in collaboration with Incyte Corporation. For additional information, please visit Merus’ website, www.merus.nl.
Contacts:
Investors:
Kimberly Minarovich
+1 646 368 8014
[email protected]
Media:
David Rosen
+1 212-600-1902
[email protected]
